Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of GB001 in chronic rhinosinusitis with or without nasal polyps
2019-001682-33Phase 2Completed
- Sponsor
- Gossamer Bio
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic rhinosinusitis (CRS), chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic chronic rhinosinusitis (ECRS) comparing GB001 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 16 in Sino-Nasal Outcome Test-22. Started Jul 2019; status: completed.
02
Drugs
GB001
03
Conditions
chronic rhinosinusitis (CRS)chronic rhinosinusitis with nasal polyps (CRSwNP)eosinophilic chronic rhinosinusitis (ECRS)
Beyond the preview
Go deeper on 2019-001682-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001682-33.